With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
Low levels of a certain thyroid hormone may have broader implications for newly diagnosed patients with multiple myeloma (MM), say study results.
According to the single-center retrospective study of 200 patients, low T3 syndrome could potentially help predict survival outcomes among these patients, with multivariate analyses showing that the syndrome was an independent factor associated with both overall (OS) and progression-free survival (PFS). The researchers noted that their findings are the first, to their knowledge, to draw a connection between low T3 syndrome and survival among patients with MM.
With survival of MM ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance. The researchers say their findings indicate that low T3 levels—an easily measured hormone—may aid in risk stratification for these patients.
The group observed significantly worse OS (34 months vs 85 months) and PFS (20 months vs 52 months) among the 80 patients (39.8%) with low T3 syndrome at baseline compared with patients without the syndrome.
“As to why low T3 syndrome at baseline was strongly associated with survival in MM patients, we suggested that it was probably due to the correlations of low T3 syndrome with not one but several known prognostic factors,” explained the researchers.
They added, “the higher inflammation state, serum β2-MG, and creatinine levels, lower hemoglobin and albumin levels, and more advanced ISS [International staging system] and [Revised]-ISS stages in low T3 syndrome patients in this study suggested that elevated inflammation, malnutrition, anemia, renal dysfunction, and more advanced disease severity stage probably could explain the predictive ability of low T3 syndrome for the prognosis in MM.”
Subgroup analyses showed that low T3 syndrome had poor implications for survival regardless of whether or not the patient received novel treatments (bortezomib and/or lenalidomide-based treatment) and for patients not receiving autologous stem cell transplantation.
The researchers found that serum FT3 was predictive of mortality during the entire follow-up period and had positive correlations with albumin and hemoglobin levels and had negative correlations with β2-MG, creatinine, neutrophil/lymphocyte ratio, and (neutrophil+monocyte)/lymphocyte ratio. The researchers explained that these findings suggest multiple factors are likely connected to low T3 syndrome in the disease.
“[Receiver operator characteristic curve] analyses showed that FT3 was a significant predictor for both death and one-year death. The optimal cut-off values of FT3 for predicting death and one-year death were 2.36 pg/mL and 2.34 pg/mL, respectively,” detailed the researchers. “Both above values were close to the lower limit of the FT3 normal range (2.3 pg/mL), which also was the value used to define low T3 syndrome in this study.”
FT4 and thyrotropin were also included in ROC analyses, although FT3 had the largest area under the curve.
Reference
Pan Q, Jian Y, Zhang Y, et al. The association between low T3 syndrome and survival in patients with newly diagnosed multiple myeloma: a retrospective study. Technol Cancer Res. Published online April 20, 2020. doi:10.1177/15330338221094422
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment
March 21st 2024In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Read More
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Read More
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
February 15th 2024The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Read More
Disability Degree, Home Health Use May Signal Need for Patient Support in MM
February 7th 2024Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).
Read More